Thymosin Alpha-1
Approved as a medicine in several other countries; not FDA-approved in the United States, and its US compounding eligibility has been restricted — a licensed pharmacy can confirm the current position.
What it is
Thymosin alpha-1 is an immune-modulating peptide originally isolated from the thymus. Unusually for this library, it is a real approved medicine — in dozens of countries, sold as Zadaxin, mostly for hepatitis B and C and as an immune adjunct — just not in the United States.
It has genuine human clinical-trial history, including US trials in sepsis and other settings. FDA restricted its availability through US compounding pharmacies in its 2023 interim-list actions, which sharply narrowed the lawful US channel. The gap between 'approved in 35 countries' and 'not approved here' makes it one of the more genuinely debatable compounds in the peptide conversation.
What researchers have actually studied it for
Hepatitis B and C, immune support in cancer care, and sepsis — in real human trials of varying size and quality across decades.
How it works
A 28-amino-acid thymic peptide that tunes T-cell maturation and function — enhancing responses where immunity is suppressed and, per some studies, tempering overactive inflammation. 'Immune modulator' fits better than 'booster': its studied role is restoring balance in specific disease states.
Where it came from
Isolated in 1977 from thymic extract during the era's hunt for immune hormones, thymosin alpha-1 was developed by SciClone largely for Asian hepatitis markets, gaining approvals across dozens of countries by the 1990s–2000s. US development kept stalling short of approval — most recently a major sepsis trial and COVID-era studies that revived interest without changing its status.
What the research record actually contains
- Controlled trials in chronic hepatitis B and C, mostly of an earlier era, supporting its foreign approvals.
- US and international trials in sepsis and severe infection with mixed results.
- Adjunct-therapy studies in oncology and vaccine response.
- The strongest human evidence file of anything in this library without a US approval.
What's known about risks
Decades of international pharmacovigilance report a benign profile — injection-site reactions lead the list. The 2023 US compounding restriction reflected regulatory-channel policy as much as new safety signal.
Where it stands legally
Approved abroad (Zadaxin) but not in the US, where the 2023 interim-list action restricted routine compounding. US access is therefore narrow and status-dependent — a licensed pharmacy holds the current answer.
Worth asking a licensed provider
- 1.For my immune concern, is there any US-approved therapy that addresses the same goal?
- 2.What is thymosin alpha-1's current compounding status, and is any lawful channel open to me?
- 3.How would we measure whether immune modulation is even working?